SVRA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Savara Inc

NASDAQ | SVRA

4.26

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 13, 2025)

$829.37M

Market Cap

-

P/E Ratio

-0.51

EPS

$4.50

52 Week High

$1.89

52 Week Low

HEALTHCARE

Sector

SVRA Chart

Recent Chart
Price Action

SVRA Technicals

Tags:

SVRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$275K
Total Revenue $0
Cost Of Revenue $275K
Costof Goods And Services Sold $275K
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $103M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

Revenue & Profitability

Earnings Performance

SVRA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $202M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $11M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $10M
Intangible Assets Excluding Goodwill $10M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $181M
Other Current Assets $4.8M
Other Non Current Assets -
Total Liabilities $41M
Total Current Liabilities $15M
Current Accounts Payable $4.5M
Deferred Revenue -
Current Debt -
Short Term Debt $116K
Total Non Current Liabilities $27M
Capital Lease Obligations $116K
Long Term Debt $27M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $27M
Other Current Liabilities $10M
Other Non Current Liabilities $87K
Total Shareholder Equity $171M
Treasury Stock -
Retained Earnings -$489M
Common Stock $173K
Common Stock Shares Outstanding $198M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$89M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $130K
Capital Expenditures $25K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$40M
Cashflow From Financing $118M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$995K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$96M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$275K
Total Revenue $0
Cost Of Revenue $275K
Costof Goods And Services Sold $275K
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $103M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

SVRA News

SVRA Profile

Savara Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Savara Inc. is a biopharmaceutical company headquartered in Austin, Texas, focused on developing innovative therapies for patients with rare lung diseases. With a commitment to addressing unmet medical needs in the field of respiratory health, Savara's pipeline includes promising candidates targeting various orphan indications. The company's strategic approach combines cutting-edge science with a patient-centric vision, positioning it as a key player in the lung disease therapeutic landscape.

NVVE
+204.60%
$0.47
LPTX
+368.57%
$2.05
TNMG
+37.18%
$0.41
CMND
+11.56%
$0.34
VINE
-16.56%
$0.44
ONDS
+19.05%
$6.56
RUBI
+16.35%
$0.23
NVDA
-3.58%
$186.86
VHAI
0.00%
$0.00
SOND
+8.82%
$0.18
PFE
-0.25%
$25.80
TSLA
-6.64%
$401.99
SOFI
-11.85%
$28.39
PLUG
-8.79%
$2.49
BITF
-17.98%
$2.60
ASST
-10.46%
$1.15
YDKG
-18.03%
$0.02
WTO
-30.89%
$0.02
INTC
-5.22%
$35.91
ACHR
-8.15%
$7.94
DRCT
+44.06%
$0.28
BYND
-9.41%
$1.01
F
-1.22%
$13.28
SGBX
+32.21%
$3.16
ETHD
+14.44%
$5.15
AXDX
-61.36%
$0.03
MGRX
-32.38%
$1.19
RGTI
-10.95%
$25.20
AMD
-4.22%
$247.96
NIO
-3.33%
$6.23
RIVN
-6.44%
$16.39
DNN
0.00%
$2.59
CSCO
+4.62%
$77.38
CIFR
-14.09%
$14.93
PLTR
-6.81%
$171.61
SNAP
-5.66%
$8.57
TLRY
-8.13%
$1.13
GRAB
-4.31%
$5.54
CAN
-10.18%
$0.97
CRCL
-4.76%
$82.19
ADAP
-15.14%
$0.05
NOK
+1.73%
$7.02
CHR
+3.90%
$0.04
T
+0.37%
$25.74
IREN
-12.65%
$48.65
ONON
+17.99%
$41.51
QBTS
-11.45%
$23.37
AAPL
-0.19%
$272.95
ASBP
-7.65%
$0.10
BBD
-0.13%
$3.67
DIS
-7.76%
$107.59
WULF
-7.59%
$11.68
SOUN
-7.70%
$12.22
BTBT
-11.26%
$2.52
CRWV
-8.29%
$78.34
HPE
-2.38%
$22.92
MARA
-1.50%
$14.41
NBIS
-6.07%
$88.63
AMZN
-2.71%
$237.58
RMBL
+60.50%
$3.21
UGRO
-18.97%
$0.24
LNW
-3.71%
$86.22
AAL
-2.89%
$13.07
ADD
-25.47%
$0.05
BAC
-2.24%
$52.89
IONZ
+20.63%
$5.67
SMCI
-7.43%
$35.09
BTE
+4.12%
$3.15
RIG
-3.14%
$4.00
SRM
+53.27%
$10.30
CLSK
-10.12%
$11.98
GPUS
-10.41%
$0.30
EPWK
-38.09%
$0.04
QS
-7.41%
$13.55
BMNR
-9.37%
$36.76
IONQ
-10.67%
$45.29
MU
-3.24%
$236.95
KVUE
+0.68%
$16.78
VZ
+0.74%
$41.10
WBD
-0.22%
$22.14
HOOD
-9.51%
$120.33
HIMS
-7.77%
$35.98
GOOGL
-2.83%
$278.57
BURU
-8.32%
$0.25
BTG
-1.79%
$4.10
MLSS
+6.11%
$0.38
AMCR
+1.96%
$8.57
TWOH
-5.66%
$0.00
WLGS
-5.57%
$0.04
RIOT
-10.21%
$13.88
QUBT
-9.96%
$10.03
NGD
-4.15%
$7.26
BE
-18.28%
$103.55
SMR
-10.93%
$23.12
APLD
-7.56%
$26.41
PLTZ
+13.00%
$7.04
JD
-1.71%
$30.71
ABEV
0.00%
$2.53
LYFT
+1.61%
$24.57
VSA
-20.34%
$0.23
NVVE
+204.60%
$0.47
LPTX
+368.57%
$2.05
TNMG
+37.18%
$0.41
CMND
+11.56%
$0.34
VINE
-16.56%
$0.44
ONDS
+19.05%
$6.56
RUBI
+16.35%
$0.23
NVDA
-3.58%
$186.86
VHAI
0.00%
$0.00
SOND
+8.82%
$0.18
PFE
-0.25%
$25.80
TSLA
-6.64%
$401.99
SOFI
-11.85%
$28.39
PLUG
-8.79%
$2.49
BITF
-17.98%
$2.60
ASST
-10.46%
$1.15
YDKG
-18.03%
$0.02
WTO
-30.89%
$0.02
INTC
-5.22%
$35.91
ACHR
-8.15%
$7.94
DRCT
+44.06%
$0.28
BYND
-9.41%
$1.01
F
-1.22%
$13.28
SGBX
+32.21%
$3.16
ETHD
+14.44%
$5.15
AXDX
-61.36%
$0.03
MGRX
-32.38%
$1.19
RGTI
-10.95%
$25.20
AMD
-4.22%
$247.96
NIO
-3.33%
$6.23
RIVN
-6.44%
$16.39
DNN
0.00%
$2.59
CSCO
+4.62%
$77.38
CIFR
-14.09%
$14.93
PLTR
-6.81%
$171.61
SNAP
-5.66%
$8.57
TLRY
-8.13%
$1.13
GRAB
-4.31%
$5.54
CAN
-10.18%
$0.97
CRCL
-4.76%
$82.19
ADAP
-15.14%
$0.05
NOK
+1.73%
$7.02
CHR
+3.90%
$0.04
T
+0.37%
$25.74
IREN
-12.65%
$48.65
ONON
+17.99%
$41.51
QBTS
-11.45%
$23.37
AAPL
-0.19%
$272.95
ASBP
-7.65%
$0.10
BBD
-0.13%
$3.67
DIS
-7.76%
$107.59
WULF
-7.59%
$11.68
SOUN
-7.70%
$12.22
BTBT
-11.26%
$2.52
CRWV
-8.29%
$78.34
HPE
-2.38%
$22.92
MARA
-1.50%
$14.41
NBIS
-6.07%
$88.63
AMZN
-2.71%
$237.58
RMBL
+60.50%
$3.21
UGRO
-18.97%
$0.24
LNW
-3.71%
$86.22
AAL
-2.89%
$13.07
ADD
-25.47%
$0.05
BAC
-2.24%
$52.89
IONZ
+20.63%
$5.67
SMCI
-7.43%
$35.09
BTE
+4.12%
$3.15
RIG
-3.14%
$4.00
SRM
+53.27%
$10.30
CLSK
-10.12%
$11.98
GPUS
-10.41%
$0.30
EPWK
-38.09%
$0.04
QS
-7.41%
$13.55
BMNR
-9.37%
$36.76
IONQ
-10.67%
$45.29
MU
-3.24%
$236.95
KVUE
+0.68%
$16.78
VZ
+0.74%
$41.10
WBD
-0.22%
$22.14
HOOD
-9.51%
$120.33
HIMS
-7.77%
$35.98
GOOGL
-2.83%
$278.57
BURU
-8.32%
$0.25
BTG
-1.79%
$4.10
MLSS
+6.11%
$0.38
AMCR
+1.96%
$8.57
TWOH
-5.66%
$0.00
WLGS
-5.57%
$0.04
RIOT
-10.21%
$13.88
QUBT
-9.96%
$10.03
NGD
-4.15%
$7.26
BE
-18.28%
$103.55
SMR
-10.93%
$23.12
APLD
-7.56%
$26.41
PLTZ
+13.00%
$7.04
JD
-1.71%
$30.71
ABEV
0.00%
$2.53
LYFT
+1.61%
$24.57
VSA
-20.34%
$0.23
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.